Review
. 2017 Dec;19(1).
doi: 10.1016/S1470-2045(17)30777-5.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)  
  • PMID: 29242041
  •     29 References
  •     116 citations

Abstract

Background: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials.

Methods: We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively. Primary outcomes were tumour response, extent of local therapy, local and distant recurrence, breast cancer death, and overall mortality. Analyses by intention-to-treat used standard regression (for response and frequency of breast-conserving therapy) and log-rank methods (for recurrence and mortality).

Findings: Patients entered the trials from 1983 to 2002 and median follow-up was 9 years (IQR 5-14), with the last follow-up in 2013. Most chemotherapy was anthracycline based (3838 [81%] of 4756 women). More than two thirds (1349 [69%] of 1947) of women allocated NACT had a complete or partial clinical response. Patients allocated NACT had an increased frequency of breast-conserving therapy (1504 [65%] of 2320 treated with NACT vs 1135 [49%] of 2318 treated with adjuvant chemotherapy). NACT was associated with more frequent local recurrence than was adjuvant chemotherapy: the 15 year local recurrence was 21·4% for NACT versus 15·9% for adjuvant chemotherapy (5·5% increase [95% CI 2·4-8·6]; rate ratio 1·37 [95% CI 1·17-1·61]; p=0·0001). No significant difference between NACT and adjuvant chemotherapy was noted for distant recurrence (15 year risk 38·2% for NACT vs 38·0% for adjuvant chemotherapy; rate ratio 1·02 [95% CI 0·92-1·14]; p=0·66), breast cancer mortality (34·4% vs 33·7%; 1·06 [0·95-1·18]; p=0·31), or death from any cause (40·9% vs 41·2%; 1·04 [0·94-1·15]; p=0·45).

Interpretation: Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered-eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy.

Funding: Cancer Research UK, British Heart Foundation, UK Medical Research Council, and UK Department of Health.

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis.
J Natl Cancer Inst, 2005 Feb 03; 97(3). PMID: 15687361
Highly Cited.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Sonographically guided clip placement facilitates localization of breast cancer after neoadjuvant chemotherapy.
L F Baron, P L Baron, +2 authors, T L Pope.
AJR Am J Roentgenol, 2000 Feb 05; 174(2). PMID: 10658738
Combined chemotherapy and radiotherapy for locally advanced breast cancer.
R D Rubens, S Sexton, +3 authors, J L Hayward.
Eur J Cancer, 1980 Mar 01; 16(3). PMID: 7371690
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
M Clarke, R Collins, +14 authors, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 Dec 20; 366(9503). PMID: 16360786
Highly Cited. Review.
Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.
Lesley A Stewart, Mike Clarke, +5 authors, PRISMA-IPD Development Group.
JAMA, 2015 Apr 29; 313(16). PMID: 25919529
Highly Cited.
Neoadjuvant chemotherapy for operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde.
Br J Surg, 2007 Aug 19; 94(10). PMID: 17701939
Review.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 Apr 12; 24(13). PMID: 16606972
Highly Cited.
Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial.
David N Danforth, Kenneth Cowan, +7 authors, JoAnne Zujewski.
Ann Surg Oncol, 2003 Jul 04; 10(6). PMID: 12839848
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).
L Mauriac, G MacGrogan, +5 authors, F Bonichon.
Ann Oncol, 1999 Mar 17; 10(1). PMID: 10076721
The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.
A R Feinstein, D M Sosin, C K Wells.
N Engl J Med, 1985 Jun 20; 312(25). PMID: 4000199
Highly Cited.
Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.
Krishna B Clough, Victor Acosta-Marín, +12 authors, Pascal Bonnier.
Ann Surg Oncol, 2015 Feb 11; 22(11). PMID: 25665949
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
N Wolmark, J Wang, +2 authors, B Fisher.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773300
Highly Cited.
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
T J Powles, T F Hickish, +7 authors, D Cosgrove.
J Clin Oncol, 1995 Mar 01; 13(3). PMID: 7884414
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.
Sarah S Mougalian, Pamela R Soulos, +7 authors, Anees B Chagpar.
Cancer, 2015 Apr 24; 121(15). PMID: 25902916
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, +3 authors, L Duchateau.
J Clin Oncol, 2001 Nov 16; 19(22). PMID: 11709566
Highly Cited.
Improved methodology for analyzing local and distant recurrence.
R Gelman, R Gelber, +2 authors, J R Harris.
J Clin Oncol, 1990 Mar 01; 8(3). PMID: 2288553
Improved estimates of floating absolute risk.
Martyn Plummer.
Stat Med, 2003 Dec 26; 23(1). PMID: 14695642
Neoadjuvant chemotherapy in operable breast cancer.
S M Scholl, B Asselain, +6 authors, P Pouillart.
Eur J Cancer, 1991 Jan 01; 27(12). PMID: 1782080
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
J C Gazet, H T Ford, +6 authors, R C Coombes.
Ann Oncol, 2001 Jul 04; 12(5). PMID: 11432629
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Response-guided neoadjuvant chemotherapy for breast cancer.
Gunter von Minckwitz, Jens Uwe Blohmer, +16 authors, Sibylle Loibl.
J Clin Oncol, 2013 Sep 05; 31(29). PMID: 24002511
Highly Cited.
Presence of a growth-stimulating factor in serum following primary tumor removal in mice.
B Fisher, N Gunduz, +2 authors, E Saffer.
Cancer Res, 1989 Apr 15; 49(8). PMID: 2702641
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.
Michael Gnant, Nadia Harbeck, Christoph Thomssen.
Breast Care (Basel), 2017 Jun 01; 12(2). PMID: 28559767    Free PMC article.
Highly Cited. Review.
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Susanne Taucher, Guenther G Steger, +12 authors, Austrian Breast and Colorectal Cancer Study Group-07.
Breast Cancer Res Treat, 2007 Dec 18; 112(2). PMID: 18080748
Patterns of Care in the Administration of Neo-adjuvant Chemotherapy for Breast Cancer. A Population-Based Study.
Guusje Vugts, Adriana J G Maaskant-Braat, +3 authors, Adri C Voogd.
Breast J, 2016 Mar 08; 22(3). PMID: 26945566
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Luca Gianni, José Baselga, +15 authors, Gianni Bonadonna.
J Clin Oncol, 2009 Apr 01; 27(15). PMID: 19332727
Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.
David Krug, René Baumann, +11 authors, Rolf Sauer.
Strahlenther Onkol, 2018 Feb 01; 194(7). PMID: 29383405
Systematic Review.
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.
Florin-Andrei Taran, Andreas Schneeweiss, +19 authors, Florian Schütz.
Geburtshilfe Frauenheilkd, 2018 Mar 27; 78(3). PMID: 29576629    Free PMC article.
Neoadjuvant treatment: the future of patients with breast cancer.
F Reyal, A S Hamy, Martine J Piccart.
ESMO Open, 2018 Jun 05; 3(4). PMID: 29862051    Free PMC article.
Progress in breast cancer-can we do better?
S F Dent.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910642    Free PMC article.
Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.
David Krug, René Baumann, +12 authors, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO).
Strahlenther Onkol, 2018 Jul 06; 194(9). PMID: 29974132
Review.
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.
Paul Gass, Michael Untch, +18 authors, Naiba Nabieva.
Geburtshilfe Frauenheilkd, 2018 Jul 31; 78(7). PMID: 30057427    Free PMC article.
Programmed Cell Death Protein-1 Predicts the Recurrence of Breast Cancer in Patients Subjected to Radiotherapy After Breast-Preserving Surgery.
Ruyi Huang, Yiyao Cui, Yujiang Guo.
Technol Cancer Res Treat, 2018 Aug 21; 17. PMID: 30122122    Free PMC article.
Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
Jianguo Lai, Hongli Wang, +2 authors, Zihao Pan.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122984    Free PMC article.
Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era.
Naomi Nakajima, Masahiko Oguchi, +7 authors, Shinji Ohno.
Adv Radiat Oncol, 2018 Sep 12; 3(3). PMID: 30202796    Free PMC article.
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.
Alexios Matikas, John Lövrot, +9 authors, Theodoros Foukakis.
Oncoimmunology, 2018 Sep 20; 7(9). PMID: 30228933    Free PMC article.
Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Houpu Yang, Lixin Zhou, +11 authors, Yuan Peng.
Medicine (Baltimore), 2018 Oct 07; 97(40). PMID: 30290661    Free PMC article.
From Standard of Care to the Neoadjuvant Model as an Innovative Platform for Exploring Promising Combinations in Breast Cancer.
Cristina Saura.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319324    Free PMC article.
Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.
Octavi Cordoba, Lourdes Carrillo-Guivernau, Carmen Reyero-Fernández.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319325    Free PMC article.
Review.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Review.
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.
Achim Wöckel, Michael P Lux, +17 authors, Hans-Christian Kolberg.
Geburtshilfe Frauenheilkd, 2018 Dec 01; 78(11). PMID: 30498278    Free PMC article.
Whole genome sequencing of breast cancer.
Maria Rossing, Claus Storgaard Sørensen, Bent Ejlertsen, Finn Cilius Nielsen.
APMIS, 2019 Jan 29; 127(5). PMID: 30689231    Free PMC article.
Review.
Music, heart rate variability, and symptom clusters: a comparative study.
Shu-Chuan Chen, Ming-Lee Yeh, Hsiu-Ju Chang, Mei-Feng Lin.
Support Care Cancer, 2019 May 03; 28(1). PMID: 31049671
Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer.
Chunfa Chen, Yuling Zhang, +3 authors, Guojun Zhang.
Cancer Biol Med, 2019 Oct 01; 16(3). PMID: 31565486    Free PMC article.
Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment.
Shazia Akbar, Mohammad Peikari, +3 authors, Anne L Martel.
Sci Rep, 2019 Oct 03; 9(1). PMID: 31576001    Free PMC article.
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Zhimin Shao, Da Pang, +18 authors, Jennifer Eng-Wong.
JAMA Oncol, 2019 Oct 28; 6(3). PMID: 31647503    Free PMC article.
Propofol-based total intravenous anesthesia did not improve survival compared to desflurane anesthesia in breast cancer surgery.
Yi-Hsuan Huang, Meei-Shyuan Lee, +5 authors, Zhi-Fu Wu.
PLoS One, 2019 Nov 08; 14(11). PMID: 31697743    Free PMC article.
Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer.
Xudong Zhu, Jinqi Xue, +7 authors, Yixiao Zhang.
J Cancer, 2019 Nov 19; 10(23). PMID: 31737103    Free PMC article.
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Alexandra S Zimmer, Neelima Denduluri.
Curr Oncol Rep, 2019 Nov 30; 21(12). PMID: 31781874
Review.
The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer.
G W Irwin, F Bannon, +15 authors, S A McIntosh.
Int J Surg Protoc, 2020 Jan 04; 18. PMID: 31897446    Free PMC article.
Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
Juan Wu, Rong Kong, +3 authors, Lingquan Kong.
Chin J Cancer Res, 2020 Jan 18; 31(6). PMID: 31949390    Free PMC article.
Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort.
Sandra Esperanza Díaz-Casas, Jorge Alberto Castilla-Tarra, +10 authors, Juan Carlos Vergel-Martinez.
Oncologist, 2019 Jul 28; 24(12). PMID: 31346133    Free PMC article.
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Christian M Seitz, Sarah Schroeder, +12 authors, Patrick Schlegel.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002293    Free PMC article.
Imaging breast cancer using hyperpolarized carbon-13 MRI.
Ferdia A Gallagher, Ramona Woitek, +41 authors, Kevin M Brindle.
Proc Natl Acad Sci U S A, 2020 Jan 23; 117(4). PMID: 31964840    Free PMC article.
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Mehra Golshan, Sibylle Loibl, +12 authors, Michael Untch.
JAMA Surg, 2020 Jan 09; 155(3). PMID: 31913413    Free PMC article.
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Nusayba A Bagegni, Yu Tao, Foluso O Ademuyiwa.
PLoS One, 2019 Sep 20; 14(9). PMID: 31536530    Free PMC article.
The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis.
Qingqing Cheng, Jiaxi Huang, +4 authors, Liangping Luo.
Front Oncol, 2020 Mar 03; 10. PMID: 32117747    Free PMC article.
Systematic Review.
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Giuseppe Gullo, Naomi Walsh, +15 authors, John Crown.
Br J Cancer, 2018 May 19; 119(3). PMID: 29773838    Free PMC article.
Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer.
Chuqian Lei, Ciqiu Yang, +11 authors, Kun Wang.
J Breast Cancer, 2020 Mar 07; 23(1). PMID: 32140269    Free PMC article.
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Simon Peter Gampenrieder, Andreas Peer, +14 authors, Richard Greil.
Breast Cancer Res, 2019 Feb 02; 21(1). PMID: 30704493    Free PMC article.
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
Ramon Colomer, Cristina Saura, +7 authors, Ana Lluch.
Oncologist, 2019 Feb 03; 24(5). PMID: 30710068    Free PMC article.
Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
Hanna Piotrzkowska-Wróblewska, Katarzyna Dobruch-Sobczak, +4 authors, Jerzy Litniewski.
PLoS One, 2019 Mar 15; 14(3). PMID: 30870478    Free PMC article.
Does adjuvant therapy reduce postmetastatic survival?
M K Fink.
Ann Oncol, 2019 May 17; 30(8). PMID: 31095301    Free PMC article.
On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Richard J Bownes, Arran K Turnbull, +3 authors, Olga Oikonomidou.
Breast Cancer Res, 2019 Jun 16; 21(1). PMID: 31200764    Free PMC article.
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy.
Sung Pil Hong, Thalia E Chan, +9 authors, Luca Magnani.
Nat Commun, 2019 Sep 04; 10(1). PMID: 31477698    Free PMC article.
Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System.
Suniza Jamaris, Leyla Akpolat-Basci, +7 authors, Hans-Christian Kolberg.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798390    Free PMC article.
Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group.
Ramy R Saleh, Michelle B Nadler, +3 authors, Eitan Amir.
Sci Rep, 2020 Mar 07; 10(1). PMID: 32139756    Free PMC article.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, +41 authors, Laura J Esserman.
JAMA Oncol, 2020 Feb 14; 6(5). PMID: 32053137    Free PMC article.
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
Serena Di Cosimo, Nicla La Verde, +16 authors, Filippo de Braud.
PLoS One, 2019 Aug 08; 14(8). PMID: 31390375    Free PMC article.
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
Anup Tank, Hannah M Peterson, +9 authors, Darren Roblyer.
Breast Cancer Res, 2020 Mar 15; 22(1). PMID: 32169100    Free PMC article.
Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer.
Nikita Wadhwani, Ismail Jatoi.
Indian J Surg Oncol, 2020 Mar 25; 11(1). PMID: 32205961    Free PMC article.
A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: A Walk Through the Trials.
Julie K Jang, Elana R Sverdlik, Naomi R Schechter.
Curr Breast Cancer Rep, 2020 Mar 28; 11(4). PMID: 32215182    Free PMC article.
The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
Yuko Nakazawa, Seshiru Nakazawa, +7 authors, Ken Shirabe.
Oncol Lett, 2020 Mar 29; 19(4). PMID: 32218821    Free PMC article.
Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival.
K Wimmer, M Bolliger, +7 authors, F Fitzal.
Ann Surg Oncol, 2019 Dec 25; 27(5). PMID: 31873929    Free PMC article.
Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T.
Erwin Krikken, Wybe J M van der Kemp, +5 authors, Jannie P Wijnen.
NMR Biomed, 2019 Mar 30; 32(6). PMID: 30924571    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer.
Parisa Malekzadeh, Kenneth Cowan, +6 authors, David N Danforth.
Am J Clin Oncol, 2020 Jan 31; 43(5). PMID: 32000167    Free PMC article.
Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
Sandra Regina Campos Teixeira, Hélio Sebastião Amâncio de Camargo Júnior, Cesar Cabello.
Radiol Bras, 2020 Apr 28; 53(2). PMID: 32336824    Free PMC article.
Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.
Xiang Ai, Xin Liao, +5 authors, Jun Jiang.
Med Sci Monit, 2020 Apr 30; 26. PMID: 32348295    Free PMC article.
IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 May 12; 10. PMID: 32391265    Free PMC article.
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Saem Hur, Ju Hee Kim, +10 authors, Hyeong-Gon Moon.
J Breast Cancer, 2020 May 13; 23(2). PMID: 32395375    Free PMC article.
Neoadjuvant Radio(chemo)therapy for Breast Cancer: An Old Concept Revisited.
Christiane Matuschek, Carolin Nestle-Kraemling, +7 authors, Wilfried Budach.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398979    Free PMC article.
Review.
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.
Chih-Chiang Hung, Youngsen Yang, +3 authors, Jie-Ru Yang.
Biochem Res Int, 2020 May 14; 2020. PMID: 32399300    Free PMC article.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Review.
Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy.
Shan Zhang, Yaohui Wang, +11 authors, Jinsong Lu.
Front Oncol, 2020 May 20; 10. PMID: 32426280    Free PMC article.
Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
Bernhard Tribukait.
BMC Cancer, 2020 May 20; 20(1). PMID: 32423477    Free PMC article.
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
Jieqiang Zhu, Levan Muskhelishvili, +2 authors, Minjun Chen.
Sci Rep, 2020 May 20; 10(1). PMID: 32424219    Free PMC article.
Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.
Ashok K Vaid, Aseem Khurana, +6 authors, Kush Gupta.
World J Oncol, 2020 Jun 05; 11(3). PMID: 32494317    Free PMC article.
Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis.
Julie Labrosse, Marie Osdoit, +4 authors, Enora Laas.
PLoS One, 2020 Jun 06; 15(6). PMID: 32502222    Free PMC article.
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Lin-Yu Xia, Qing-Lin Hu, +2 authors, Xiao-Shi Li.
World J Surg Oncol, 2020 Jun 17; 18(1). PMID: 32539858    Free PMC article.
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Alex Anh-Tu Nguyen, Vignesh A Arasu, +8 authors, Nola M Hylton.
Tomography, 2020 Jun 18; 6(2). PMID: 32548286    Free PMC article.
Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.
Jennifer G Whisenant, Jason M Williams, +6 authors, Thomas E Yankeelov.
Tomography, 2020 Jun 18; 6(2). PMID: 32548293    Free PMC article.
Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
Erik Heeg, Perla J Marang-van de Mheen, +5 authors, Marie-Jeanne T F D Vrancken Peeters.
Int J Cancer, 2019 Nov 14; 147(1). PMID: 31721193    Free PMC article.
Locoregional Management After Neoadjuvant Chemotherapy.
Monica Morrow, Atif J Khan.
J Clin Oncol, 2020 May 23; 38(20). PMID: 32442069    Free PMC article.
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
Benjamin D Smith, Matthew P Goetz, Judy C Boughey.
J Clin Oncol, 2020 May 23; 38(20). PMID: 32442073    Free PMC article.
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca Parisi, Maria Grazia Razeti, +7 authors, Matteo Lambertini.
Clin Med Insights Oncol, 2020 Jul 11; 14. PMID: 32647477    Free PMC article.
The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis.
Yan Li, Yidong Zhou, +4 authors, Qiang Sun.
Front Oncol, 2020 Jul 18; 10. PMID: 32676452    Free PMC article.
Systematic Review.
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
David M Kurtz, Mohammad S Esfahani, +20 authors, Ash A Alizadeh.
Cell, 2019 Jul 10; 178(3). PMID: 31280963    Free PMC article.
Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - A randomized controlled trial.
Maria Fjell, Ann Langius-Eklöf, +2 authors, Kay Sundberg.
Breast, 2020 Apr 05; 51. PMID: 32247251    Free PMC article.
Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters.
Harry D Bear, Kandace P McGuire.
Ann Surg Oncol, 2019 Apr 26; 26(8). PMID: 31020504    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Nina Ditsch, Michael Untch, +42 authors, Achim Wöckel.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558897    Free PMC article.
Review.
Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy.
Xiaosheng Zhuang, Chi Chen, +10 authors, Kun Wang.
Transl Oncol, 2020 Aug 08; 13(11). PMID: 32759037    Free PMC article.
Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ramona Woitek, Mary A McLean, +27 authors, Ferdia A Gallagher.
Radiol Imaging Cancer, 2020 Aug 18; 2(4). PMID: 32803167    Free PMC article.
Early stage triple negative breast cancer: Management and future directions.
Lubna N Chaudhary.
Semin Oncol, 2020 Jun 09; 47(4). PMID: 32507668    Free PMC article.
Review.
Engagement in an Interactive App for Symptom Self-Management during Treatment in Patients With Breast or Prostate Cancer: Mixed Methods Study.
Marie-Therése Crafoord, Maria Fjell, +2 authors, Ann Langius-Eklöf.
J Med Internet Res, 2020 Jul 15; 22(8). PMID: 32663140    Free PMC article.
Management of the Axilla after Neoadjuvant Systemic Therapy.
Trista J Stankowski-Drengler, Heather B Neuman.
Curr Treat Options Oncol, 2020 May 29; 21(7). PMID: 32462230    Free PMC article.
Review.
Breast Cancer Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy by Receptor Subtype: A Scoping Review.
Trista J Stankowski-Drengler, Devon Livingston-Rosanoff, +3 authors, Heather B Neuman.
J Surg Res, 2020 May 19; 254. PMID: 32422430    Free PMC article.
Review.
Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Yanding Zhao, Evelien Schaafsma, Chao Cheng.
Cancer Med, 2020 Jul 22;. PMID: 32692484    Free PMC article.
Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients.
Shujun Chen, Zhenyu Shu, +5 authors, Feng Shao.
Front Oncol, 2020 Sep 15; 10. PMID: 32923392    Free PMC article.
Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study.
Ben-Jie Shan, Xia-Bo Shen, +8 authors, Yue-Yin Pan.
Gland Surg, 2020 Sep 22; 9(4). PMID: 32953611    Free PMC article.
Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer.
Jyotsna Bhudia, Rob Glynne-Jones, Thomas Smith, Marcia Hall.
Clin Colon Rectal Surg, 2020 Sep 25; 33(5). PMID: 32968364    Free PMC article.
Review.
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Nicholas Pulliam, Jessica Tang, +6 authors, Kenneth P Nephew.
Cancers (Basel), 2019 Jan 10; 11(1). PMID: 30621214    Free PMC article.
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.
Silvia Antolín, Benigno Acea, +7 authors, Lourdes Calvo.
Breast Cancer (Dove Med Press), 2019 Jan 16; 11. PMID: 30643452    Free PMC article.
Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.
Kowsi Murugappan, Apoorva Saboo, Lu Kuo, Owen Ung.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687624    Free PMC article.
Review.
Primary medical therapy and breast conservation treatment: the medical oncology perspective.
Nan Soon Wong.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687629    Free PMC article.
Review.
Impact of clinical and pathological factors on local recurrence after breast-conserving treatment: CT-based localization for a tumor bed boost yielded better local control when compared with a surgical scar.
Lize Wang, Jinfeng Li, +4 authors, Tao Ouyang.
J Cancer, 2019 Feb 06; 10(3). PMID: 30719169    Free PMC article.
Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research.
Cigdem Selli, Andrew H Sims.
Breast Cancer (Auckl), 2019 Mar 01; 13. PMID: 30814840    Free PMC article.
Review.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Review.
Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient.
Omar Hamdy.
J Breast Cancer, 2019 Apr 04; 22(1). PMID: 30941242    Free PMC article.
Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy.
Yi-Wei Tong, Gen Wang, +7 authors, Kun-Wei Shen.
Onco Targets Ther, 2019 Jun 14; 12. PMID: 31190894    Free PMC article.
Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment.
Vladimir M Perelmuter, Liubov A Tashireva, +4 authors, Nadezhda V Cherdyntseva.
Breast Cancer (Dove Med Press), 2019 Jul 17; 11. PMID: 31308736    Free PMC article.
Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.
Katarzyna Dobruch-Sobczak, Hanna Piotrzkowska-Wróblewska, +6 authors, Jerzy Litniewski.
J Ultrason, 2019 Jul 30; 19(77). PMID: 31355579    Free PMC article.
Breast Edema Following Breast-Conserving Surgery and Radiotherapy: Patient-Reported Prevalence, Determinants, and Effect on Health-Related Quality of Life.
Danny A Young-Afat, Madelijn L Gregorowitsch, +9 authors, Helena M Verkooijen.
JNCI Cancer Spectr, 2019 Jul 31; 3(2). PMID: 31360894    Free PMC article.
Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis.
Lin He, Qian Wu, +3 authors, Yuhua Song.
Cancer Manag Res, 2019 Sep 12; 11. PMID: 31507328    Free PMC article.
Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience.
Salvatore Del Prete, Michele Caraglia, +11 authors, Raffaele Addeo.
Oncol Lett, 2019 Sep 14; 18(4). PMID: 31516598    Free PMC article.
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
Debora de Melo Gagliato, Xiudong Lei, +4 authors, Mariana Chavez-MacGregor.
Oncologist, 2020 May 21;. PMID: 32431013    Free PMC article.
Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
José Bines, Isabele A Small, +9 authors, Martin Bonamino.
Oncologist, 2020 Jun 02;. PMID: 32476183    Free PMC article.
Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
Ozkan Alan, Tugba Akin Telli, +13 authors, Perran Fulden Yumuk.
World J Surg Oncol, 2020 Sep 11; 18(1). PMID: 32907593    Free PMC article.
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Rubina Manuela Trimboli, Paolo Giorgi Rossi, +4 authors, Francesco Sardanelli.
Insights Imaging, 2020 Sep 26; 11(1). PMID: 32975658    Free PMC article.
Review.
Update on breast cancer diagnosis and management: new topics for primary care.
Julie Cox, Amir Bhatti, Yitka Graham, Daniela Lee.
Br J Gen Pract, 2020 Oct 03; 70(699). PMID: 33004378    Free PMC article.
Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer?
Angelena Crown, Shirin Muhsen, +4 authors, Mary L Gemignani.
Ann Surg Oncol, 2020 Aug 09; 27(12). PMID: 32767225    Free PMC article.
Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy.
Zhen-Yu Wu, Hee-Jeong Kim, +11 authors, BeomSeok Ko.
JAMA Surg, 2020 Oct 15;. PMID: 33052412    Free PMC article.
Early Prediction of Tumor Response to Neoadjuvant Chemotherapy and Clinical Outcome in Breast Cancer Using a Novel FDG-PET Parameter for Cancer Stem Cell Metabolism.
Chanwoo Kim, Sang-Ah Han, +2 authors, Deog Yoon Kim.
J Pers Med, 2020 Sep 23; 10(3). PMID: 32957507    Free PMC article.
A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer.
Dimitrios Korentzelos, Amanda M Clark, Alan Wells.
Int J Mol Sci, 2020 Oct 08; 21(19). PMID: 33022920    Free PMC article.
Review.
Chinese breast cancer surgery: clinical practice and research.
Ling Xin, Jia-Yi Li, Zhi-Gang Yu, Yin-Hua Liu.
Chin Med J (Engl), 2020 Aug 10; 133(19). PMID: 32769500    Free PMC article.
Neoadjuvant chemotherapy: practice and thinking for Chinese patients with early breast cancer.
Xue-Fei Wang, Song-Jie Shen, +4 authors, Qiang Sun.
Chin Med J (Engl), 2020 Aug 10; 133(19). PMID: 32769502    Free PMC article.
Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam.
Huyen Thi Phung, Hoa Thi Nguyen, +3 authors, Chu Van Nguyen.
Breast Cancer (Dove Med Press), 2020 Oct 30; 12. PMID: 33116813    Free PMC article.
Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis.
Jin Hong, Jiayi Wu, +6 authors, Kunwei Shen.
J Cancer, 2020 Oct 31; 11(23). PMID: 33123282    Free PMC article.
FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction.
Shuo Liu, Haobin Wang, +7 authors, Shijing Yue.
Cell Death Dis, 2020 Sep 27; 11(9). PMID: 32978372    Free PMC article.
Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer.
Archya Dasgupta, Stephen Brade, +14 authors, Gregory J Czarnota.
Oncotarget, 2020 Nov 05; 11(42). PMID: 33144919    Free PMC article.
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.
Xiangmei Zhang, Jingping Li, +4 authors, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145271    Free PMC article.
Landmark trials in the medical oncology management of early stage breast cancer.
Whitney Hensing, Cesar A Santa-Maria, Lindsay L Peterson, Jennifer Y Sheng.
Semin Oncol, 2020 Sep 17; 47(5). PMID: 32933761    Free PMC article.
Review.